Dr. Tarek Shalaby is the founder and the Editor-in-Chief of the Journal of Unexplored Medical Data. Dr. Shalaby obtained his MD-PhD degree in molecular and cell biology at the University of Bern, Switzerland. He works at the Department of Oncology, University Children's Hospital, Zurich, Switzerland. Dr. Shalaby is dedicated to pediatric neuro-oncology research, and focuses on molecular genetics of children’s brain tumors. He is one of the founding members of the Swiss Pediatric Oncology Group (SPOG) tumor bank and the Childhood Liver Tumors Strategy Group- SIOPEL tumor bank.
Molecular genetics of childhood meduloblastoma; Molecular biology; Cell biology; Tumor tissue banking
Dr. Said-Al-Naief is currently a Professor & Chair, Pathology & Radiology at Oregon Health Sciences SOD, director of Oral and Maxillofacial Pathology Laboratory, Professor at OHSU School of Medicine & Staff at OHSU Hospital. He had served as a Professor of Oral Diagnosis, Radiology and Pathology @ LLU School of Dentistry & as an Associate Professor at Loma Linda U. Sch. of Medicine, Dept. of Anatomy & Pathology- Head & Neck Pathology from Jan 2014 till Sept. 2015 . He had had most recently served as an Assoc. Professor & Director of OMF Pathology Lab/ Oral Medicine at the U. of Pacific, in San Francisco CA. He maintains active licensure in CA, AL, Illinois, WI.& NY & OR .
Head and Neck tumor
MD. Abdelraheim Attaai graduated in veterinary medicine and animal surgery in 2002 from Assiut University, Egypt. He started his scientific career in the field of comparative neuroanatomy, and completed his MD thesis on (Comparative Morphological Studies on the Cerebellum in Some Bird Species) and obtained his Master Degree (MSc) in 2010 from the Department of anatomy and histology, Assiut University. Now, he is continuing his professional education at the institute of anatomy and cell biology, Freiburg University, Germany, where he is conducting his Ph.D. in molecular neuroimmunology and his PhD is expected to be completed in October 2017.
His research interest is in the field of neuroimmunology (development of microglia, function of microglia in the nigrostriatal system, role of TGFb in microglia development, targeting of microglia for treatment of Neurodegenerative diseases). First, he examined the development of microglia in the nigrostriatal system. Then, he started collaboration with the National Institute for Physiological Sciences, Okazaki, Aichi, Japan to investigate the development of the nigrostriatal system in microglia-depleted mice brains, in a trial to elaborate the function of microglia during the development of the nigrostriatal system. Recently, he has focused his scientific interests on the TGFb and its role in the development and maturation of microglia. The great importance of his research is to better understand the role of microglia in development of the nigrostriatal system, which may be targeted for the treatment of Parkinson's disease.
Molecular neuroimmunology; Microglia studies; Molecular techniques both in vivo and in vitro; PCR; RNA isolation and microarray analysis; Flow cytometry; Immunohistochemistry; Histopathology and image analysis; Western blot, and Apoptosis.
Serving as an editorial board member of JUMD.
Scientific reviewer for Cells Tissues Organ.
Presented a talk in the 111th Annual Meeting of the Anatomisches Gesellschaft -held in göttingen 2016- Germany, and is frequently invited as a speaker at some international conferences.
Scholarship Award from the Egyptian ministry of higher education to conduct the PhD abroad.
Recognized as one of the top student in MSc and BS courses.
Jian-Guo Chen, MD, MPH, is a Professor, Chief of Department of Epidemiology, Vice Director of Nantong Cancer Institute, Nantong Tumor Hospital of Nantong University; and Research Fellow and Chief, Qidong Cancer Registry; Former Vice Director of Qidong Liver Cancer Institute, China. Graduated from Nantong Medical College, and Shanghai Medical University. He once majored in Epidemiology at Johns Hopkins School of Public Health. He was a Visiting Scientist at IARC in early 2000’s. He has been engaging in cancer research for decades, with related domestic and international research projects.
Epidemiology; Public health; Cancer research
Prof. Chen is an Awardee of “the Development and Contribution of Public Health and Preventive Medicine” awarded by China Preventive Medicine Association, and an Expert receiving Special Government Allowances of State Council of China. He is Chief of “Expert Team of Early-Diagnosis & Treatment for Liver Cancer, Ministry of Health of China”; Committeeman of Liver Cancer Society, China Anti-Cancer Association; Committeeman of China Medicinal Biotech Association Biobank Branch; Vice President of “Nantong Anti-Cancer Association”, and Chairman of “Nantong Tumor Epidemiology Society”.
Juel Chowdhury began his professional education at the Gulf Medical University, UAE where he received his first profession degree in medicine (Doctor of Medicine). Since then, his works have led him to associate with Nobel laureate Dr. Ferid Murad and many well-known scientists such as Dr. Robert Winn Director of UI health Chicago. He is the founder and president of Oncomarks.org an online professional network with an open access journal for the oncologists. His innovative iGenX lab is a gene research lab based on data-mining and data analysis of the various gene-chip experiments. Reviewer of well known journals like Tumor Biology and JCMT. Editorial Board member of JUMD, and many professional societies like ASCO and ISOBM. He was the director of ISOBM (International society of oncology and biomarkers) 2016 congress held in Chicago and also the member of Organizing Committee for the upcoming ISOBM 2017 congress which will be hosted in Brazil. He is an expert in Botulinum Toxin and Dermal Fillers, facial reconstruction and hair transplant procedures from Ohio,USA and Poland. He also contributed as an Organizing committee of 14th and upcoming 15th Transitional medicine and oncologist meet, San Francisco, CA.
Head and neck cancer; Lung and upper aerodigestive tumors; Labyrithin biology in huHead & neck, lung & upper aero digestive tumors, tumor stem cells. Nitric oxide in tumor environmentman tumors; Lasers and PDT; Human tumor stem cells
ISOBM 2016 Scientific Merit Award, Chicago, IL.
14th Transitional medicine and oncologist meet Best Poster Presenter Award. San Francisco, CA.
Award of Excellence in recognition of outstanding services rendered in organizing 14th Annual Conference on Transitional medicine and oncologist meet. San Francisco, CA.
Tengku Ahmad Damitri graduated in Biochemistry in 2003, MSc in Pathology in 2008 and PhD in Molecular Pathology in 2015. His expertise in biochemistry and molecular pathology, especially on diabetic patient and breast cancer. Has vast experience on in vivo and in vitro study of breast cancer, focusing on apoptosis and angiogenesis pathway. Skillful on molecular techniques such as Western blot, flow cytometry as well as biochemistry analysis, histopathology, miRNA and biomarkers. 15 years experience in research grant management locally and internationally.
Brest cancer; Diabetes mellitus type 2; Cell culture; Immunohistochemistry; Molecular pathology; Histopathology; Apoptosis mechanism; Breast cancer animal model; MicroRNA & biomakers
1: Best oral presenter at Clinical Biochemist conference in 2006.
2: Poster award for poster presentation at APIAP 2015 The 9th Asia Pacific International Academy of Pathology Congress.
Dr. Lingling Fan got her Master Degree in Pharmacology at Zhejiang University, China and got her Ph.D. Degree in Biochemistry and Molecular Biology at Huazhong University of Science and Technology, China. Her Ph.D. thesis work was done at University of California at San Francisco, USA. Now she is doing this Postdoctoral Research at University of Maryland at Baltimore.
Liver stem cell/cancer; Prostate cancer; Epigenetic regulation; Signaling pathway
I attended Weifang Medical University for my MD and obtained MSc in Neurology from Central South University in China. I received my PhD in Neuroscience from University of Houston. I am currently doing postdoctoral research at Stanford University.
Clinical neurology and neuroscience research.
Md. Golam Hafiz graduated from Mymensingh Medical College, under Dhaka University, Bangladesh in 1984, one of the oldest medical college of Pakistan (One of the eight medical colleges). He completed his post graduate residency training in Pediatric Hematology and Oncology from Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh in 2000. He obtained his Doctor of Medicine (MD) in Pediatric Hematology and Oncology from the Department of Pediatric Hematology and Oncology under Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh in 2006. He completed his MD thesis on “Predictive Value of Serum Lactate Dehydrogenase in Childhood Acute Lymphoblastic Leukemia” from BSMMU in 2006.
Dr. Md. Golam Hafiz has more than 20 year’s practical experience in the field of Pediatric Hematology and Oncology. He is working as Associate Professor in the Department of Pediatric Hematology and Oncology of Bangabandhu Sheikh Mujib Medical University since 2013. He authored more than 40 publications in National and International Medical Journal. Most of them are Indexed Medicus and the first author.
He is appointed as editorial board member in twelve different national and international medical journals. He reviewed about seventy manuscripts from home and abroad. He has been invited to lecture about the topics in several institutions. He is actively involved in the development of research and electronic progress at his institution.
He has professional responsibilities to take care of patients, teaching of post graduate students, attending in workshops, seminar, and symposium elsewhere in the country and abroad, attending in the academic and other professional activities.
He has research interest in the field of Pediatric Hematology and Oncology (acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, iron deficiency anemia, thalassemia, immune thrombocytopenic purpura).
My research interests lie with immunology and liver fibrosis. My interests in liver fibrosis research focus on the use of intrahepatic administration of collagenase for reversal of liver fibrosis and this work was one of the earliest that established proof-of-principle of these potential therapeutic agents. My immunological interest lie with double-stranded RNA induced immune response and its potential application in anti-virus and/or anti-cancer immunotherapy.
Immunology; Vaccine adjuvant; Immunotherapy; Liver fibrosis
Hepatocellular carcinoma; Medical oncology; Clinical oncology; Translational medicine; Tumor Biology; Hepatitis; Cancer biomarkers; Tumors; Cancer cells metastasis; Tumor angiogenesis; Cancer diagnostics; Cancer cell biology; Tumor microenvironment; Tumor markers; Molecular oncology; Immunohistochemistry; Prognosis; Personalized medicine; Cancer cell signaling; Protein biomarkers; Cancer biology; Prognostic markers; Cancer metastasis; Oncogenetics
Anesthesia and pain medicine
Dr. Rui Li is currently a postdoctoral researcher at Department of Neurology, University of Pennsylvania. He completed his M.D at Harbin Medical University, China and Ph.D at McGill University, Canada. His research focused on roles of B cells in multiple sclerosis.
Immunology; Autoimmunity; Autophagy; Stem cell; Melanoma
Sep. 2009 Recruitment award (McGill University)
Dec. 2010 Travel award (Neuroinflammation training program, NITP)
2010 ~ 2012 Graduate studentship award (NITP)
May. 2012 7th Annual NITP symposium (3rd place)
June. 2013/2014/2016 Travel award, Annual meeting of FOCIS
Nov. 2012 / 2014 Travel award, International Congress of Neuroimmunology
2015 National Award for Outstanding Self-Financed Students Abroad
2016 National Bank Postdoctoral fellowship
The work of Dr. Maes covers phenomenological and epidemiological aspects of mood disorders (e.g. depression, panic disorder and post-traumatic stress disorder) and the supra-multi-disciplinary field of “pathway and drug discovery processes” in depression, mania, anxiety disorders, stress and schizophrenia, and more particularly the immune-inflammatory pathways and its connections and sequels. Dr. Maes is a clinician and translational scientist whose works ranges from epidemiological and clinical research projects, case-control studies and pharmacological trials, to rodent and molecular experiments.
My major research activities involve the development of integrative oncology clinical medicine [bridging the gap between Western medicine and complementary and alternative medicine (CAM)], with a particular interest in cancer survivorship. A significant proportion of cancer survivors are using CAM in the Australia and globally, although scientific evidence is lacking.
Since 2005, I have been involved in 26 studies evaluating CAM therapies, including 11 studies with Medical Qigong trial and 5 studies with acupuncture trial. The two major studies that impacted my research career were the “examination of patient-doctor communication about the use of CAM by cancer patients” and the “evaluation of Medical Qigong’s (MQ) effect on the wellbeing of cancer survivors.” The first study surveyed (n=381) cancer patients from oncology departments at three university teaching hospitals. This study found that a substantial proportion of cancer patients (65%) used at least one form of CAM therapy, but a large number of them (80%) did not disclose their use of CAM to their health care providers. Most healthcare professionals are concerned about potential herb- or vitamin- drug interactions during active cancer treatment. The main reason for the use of CAM was to extend cancer patient survival. One interesting finding was that patients who discussed their use of CAM with their oncologist were more satisfied with their consultation than those who had not. The second study, a randomised control trial (RCT) of 162 cancer survivors, evaluated the safety and efficacy of MQ in cancer survivors. This study found that MQ had a positive influence on QOL, psychological and physical functioning, and led to a decrease in inflammation levels among cancer survivors. Overall, these studies suggested that integrative oncology clinical medicine can increase survivors' satisfaction and lead to improved QOL in the cancer population. The significance of my integrative oncology clinical medicine approach was recognized nationally and internationally in the oncology community, including: American Society of Oncology (ASCO), Clinical Oncological Society of Australia (COSA), European Society for Medical Oncology (ESMO) and the Society of Integrative Oncology (SIO), as well as academic communities and cancer survivors. After the recognition of the importance of integrative oncology clinical medicine, I have introduced integrative oncology services at Sydney University teaching hospitals, RNSH and Sydney Adventist Hospital, and provided integrative oncology clinical services for the first time in Australia. I was also involved in the development of the CAM education program for medical students at Sydney Medical School and have been an advisor during the development of the integrative medicine centre at LifeHouse, RPAH. Currently I am also involved in developing the Centre for Integrative Medicine and Research initiated by the Prof Bruce Robinson, dean of Sydney Medical School.
I, a Clinical Associate Professor at Sydney Medical School, research fellow of medicine at Dana-Farber Cancer Institute (DFCI), Harvard Medical School, have been involved in multiple CAM research projects including acupuncture, herb-drug interaction, and Qigong mind-body medicine. I received several international and domestic research awards and am currently involved in writing three NIH grant applications with Prof. Rosenthal at Dana-Farber Cancer Institute (DFCI) in collaboration with Massachusetts General Hospital (MGH), Benson-Henry Institute for Mind-Body Medicine, Beth Israel Deacons Medical Center (BIDMC) and Harvard Medical School. I am also serving as a consultant for Qigong study at Arizona State University, MGH, Geisel School of Medicine at Dartmouth, University of Downtown Houston and Yale University. Recently, I received “Integrative Medicine Research Collaboration Project Award ($300,000) from the Comprehensive and Integrative Medicine Institute in Korea. This project will explore the feasibility of acupuncture for neuropathy in women with breast cancer and examine the herb-drug interaction in- vitro and in-vivo model. I am also awarded research fellowship to conduct integrative and complemenary medicine research as well as introduce acupunctre services at the Northern Sydney Cancer Center, RNSH.
Integrative oncology clinical medicine
Dr. Omar is a US Board-certified Neurologist and Neurological Oncologist with specialized training in Endovascular Neurosurgery. He completed his MD at the University of Cairo with Distinction, a PhD in cellular and molecular neurosciences from the University of Ottawa, Canada, a postdoctoral fellowship at the University of Ottawa and a Masters and clinical fellowship in Endovascular Neurosurgery from the University of Oxford. He also completed a Neurology residency and chief residency at the University of Missouri – Columbia and a clinical fellowship in Neurological Oncology at the world-renowned Princess Margaret Hospital – University of Toronto.
Dr. Omar’s main research interests include the development of innovative endovascular neurosurgical approaches for the management of brain and spinal cord malignancies. He developed an innovative molecularly-targeted approach for the management of surgically unresectable spinal cord hemangioblastomas for which he was named “Medical Innovator” for the year 2013. He also developed a novel in vivo model for examining cellular and subcellular dynamics involving endogenous neural stem cells following traumatic and ischemic insults to the brain. The model was subsequently used to develop methods for neural circuit reconstruction following brain damage. For his work, he won the highly coveted Canadian Institutes for Health Research (CIHR) national postdoctoral award and was ranked 6th across Canada in the year 2000.
Dr. Omar has published extensively in the areas of cellular and molecular neurosciences, neurooncology and endovascular neurosurgery. He also presented research both nationally and internationally and is frequently an invited speaker at major international conferences.
Neurology and Neuro oncology
Named “Medical Innovator” for 2013 by the Sangamon County Medical Society and the Springfield Mayor for “Innovations in the treatment of brain and spinal cord tumors”. Honored in an award ceremony by the Mayor of Springfield, Mike Houston on March 7, 2013.
Dr. Papachristodoulou is a versatile, analytical and hard-working PhD candidate with a practical hands-on approach, who always preserves to achieve the best results. Able to work efficiently within a team as well as independently with minimal or no supervision. Excellent communication and problem- solving skills achieved through several successful collaborative research projects. Proven ability to manage and complete projects to the highest standard, with rigorous experimental documentation and within the agreed deadlines.
Glioblastoma research in vitro and in vivo; Pre-clinical evaluation of novel therapeutic approaches against cancer and specifically glioblastoma
Oral biomarkers in oral cancer
Jean-Marc Sabatier is a Director of research at the French CNRS, with PhD and HDR degrees in Biochemistry and Microbiology. He headed several academic research teams (CNRS, INSERM and University), as well as a combined academic-industry research laboratory devoted to the engineering of therapeutic peptides (ERT62, Marseilles, France). He was also a Director of Research for several French private companies as well as a Canadian public company. He acts as a Consultant for top pharmaceutical and cosmetic companies. Dr. Sabatier works in the field of animal toxins. He so far contributed to several books in toxinology and virology, and more than 160 scientific articles, 180 communications, and 53 patents in both biology and chemistry. He is a member of 36 Editorial Boards of scientific journals, such as ‘Peptides’, ‘Toxins’, ‘Molecules’ and the ‘Journal of Biological chemistry’. He acts as the Editor-in-Chief of the journal ‘Infectious Disorders – Drug Targets’. He also reviewed articles submitted for publication in 76 international journals and acts as an expert for numerous institutions (ANR, CEA, CNRS, MRC, ISF, BARD, AIRD, IPT, Pasteur Institutes, Ville de Paris, Region Languedoc-Roussillon, Fondation Arthritis, etc.). He won the ‘Citizen of the Year Award’ from the Nouvel Economiste (1994) for his work on antivirals. He is a member of a dozen scientific societies, such as the ‘American Peptide Society’ (charter member), ‘European Peptide Society’, ‘American Society for Microbiology’, ‘Biochemical Society’ and ‘New-York Academy of Sciences’.
Drug design and synthesis (peptides and related compounds); Optimization of peptide structure/conformation (to improve bioactivity, selectivity, solubility, and/or stability); Peptide and protein engineering; Development of peptide-based in vitro assays (diagnostic tests, etc.); Toxinology; Evaluation of research projects
professional membership: The International Neuropeptide Society; The New-York Academy of Sciences; American Society for Microbiology; American Peptide Society (charter member); American Society for Biochemistry and Molecular Biology (on behalf of the editor of J. Biol. Chem.); Biochemical Society (on behalf of the editor of The Biochemical Journal); Federation of American Societies for Experimental Biology; European Peptide Society; International Society on Toxinology; Société Française des Peptides et des Protéines; Société Française de Biochimie et Biologie Moléculaire; Société Française de Microbiologie; Groupement d'étude des polypeptides actifs; Association pour la Promotion de la Recherche en Interactions Cellulaires.
Oral and maxillofacial pathology; Evaluation of bio-impedance in oral premalignant and malignant lesions; Assessment of vasculature in oral squamous cell carcinoma; Qualitative study on dental records maintained by general dental practitioners in Pune; Cannabalism in oral squamous cell carcinoma
Dr. Tian got his Master degree of Nursing at Tianjin University of Traditional Chinese Medicine. He accepted the training of Evidence-based medicine in the Systematic Review Solutions Ltd. (SRS). He has been engaged in clinical trials and systematic reviews of Nursing and Nutrition. He has performed several systematic reviews and meta-analyses and focused on development of evidence-based nursing protocol. He has participated 2 provincial foundations and gained several awards. He has published about 35 papers, severed as editorial board member for three academic journals and acted as referee of more than five peer-reviewed journals. Now, he is the committee member of Evidence-based Society, China International Exchange and Promotive Association for Medical and Health Care (CPAM).
Nursing for orthopedic and cancer; Evidence-based healthcare; Research design clinical trials; Nutrition for orthopedic; Perioperative nutrition support for cancer
Guo-Gang Xing earned his Ph.D. Degree at Xi'an Jiaotong University in 2001. From 2001-2003, he received postdoctoral training at the Neuroscience Research Institute of Peking University where he subsequently served as a lecturer and conducted research in the department of neurobiology. From 2004-2006, he received postdoctoral training at Sanford-Burnham Medical Research Institute and the University of Wisconsin-Madison in USA. Dr. Xing joined the Neuroscience Research Institute of Peking University as an associate professor of neurobiology in 2004 and obtained the full professor in 2013.
Dr. Zhou received Ph.D. in Statistics at Columbia University in 2011. He has substantial research experience in medical sciences for clinical trial design and statistical data analysis. He was Biostatistics Core co-director of MDACC Lymphoma SPORE and supports several flagship projects of glioblastoma moonshot and B-cell lymphoma moonshot at MDACC as a co-investigator/lead biostatistician.
Bayesian hierarchical modeling and model selection; nonparametric statistics; longitudinal data analysis; dynamic prediction in clinical survival analysis; design and analysis of clinical trials; statistical methods for determining drug interaction in combination studies